Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of Recifercept in Healthy Chinese Participants
NCT05061277Phase 1Withdrawn
- Sponsor
- Pfizer
- Start
- Oct 2023
- Primary completion
- Dec 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of recifercept in achondroplasia (ACH), sponsored by Pfizer. Primary endpoints: Maximum Observed Concentration, Time for Cmax and 6 more. Planned start Oct 2023; status: withdrawn.
02
Drugs
recifercept
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT05061277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05061277.